文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

基于光学相干断层扫描的厚脉络膜新生血管病变与息肉样脉络膜血管病变的误诊和形态学鉴别。

Optical coherence tomography-based misdiagnosis and morphological distinction in pachychoroid neovasculopathy vs. polypoidal choroidal vasculopathy.

机构信息

Department of Ophthalmology, University Hospital, LMU Munich, Munich, Germany.

出版信息

Eye (Lond). 2023 Nov;37(16):3435-3441. doi: 10.1038/s41433-023-02529-5. Epub 2023 May 8.


DOI:10.1038/s41433-023-02529-5
PMID:37156864
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10630494/
Abstract

PURPOSE: To evaluate the rate of misdiagnosis of aneurysmatic pachychoroid type 1 choroidal neovascularization/polypoidal choroidal vasculopathy (PAT1/PCV) among cases diagnosed as non-aneurysmatic pachychoroid neovasculopathy (PNV) and to define optical coherence tomography (OCT) features facilitating their distinction. METHODS: The database of the Department of Ophthalmology, Ludwig-Maximilians University Munich, was screened for patients diagnosed with PNV. Multimodal imaging was screened for the presence of choroidal neovascularization (CNV) and aneurysms/polyps. Imaging features facilitating the diagnosis of PAT1/PCV were analysed. RESULTS: In total, 49 eyes of 44 patients with a clinical PNV diagnosis were included, of which 42 (85.7%) had PNV and 7 (14.3%) represented misdiagnosed PAT1/PCV. SFCT was comparable (PNV: 377 ± 92 vs. PAT1/PCV: 400 ± 83 µm; p = 0.39). Whereas no difference was detected in total pigment epithelium detachment (PED) diameter (p = 0.46), maximum PED height was significantly higher in the PAT1/PCV group (199 ± 31 vs. 82 ± 46, p < 0.00001). In a receiver operating characteristic (ROC) analysis, the optimum cutoff for defining "peaking PED" was 158 µm with an area under the curve of 0.969, a sensitivity of 1.0 (95% CI: 0.59-1.0), and a specificity of 0.95 (95% CI: 0.84-0.99). Sub-retinal hyperreflective material (SHRM; p = 0.04), sub-retinal ring-like structures (SRRLS; p < 0.00001), and sub-RPE fluid (p = 0.04) were significantly more frequent in eyes with PAT1/PCV. CONCLUSION: A relevant percentage of eyes diagnosed with PNV might instead suffer from PAT1/PCV. The detection of a maximum PED height ("peaking PED") exceeding approximately 150 µm, SHRM, SRRLS, and sub-RPE fluid might greatly aid in the production of a more accurate diagnosis.

摘要

目的:评估将诊断为非动脉瘤性厚脉络膜新生血管(PNV)的病例误诊为动脉瘤性厚脉络膜 1 型脉络膜新生血管/息肉样脉络膜血管病变(PAT1/PCV)的误诊率,并确定有助于两者区分的光学相干断层扫描(OCT)特征。

方法:筛选慕尼黑路德维希-马克西米利安大学眼科数据库中诊断为 PNV 的患者。对多模态成像进行筛查,以确定是否存在脉络膜新生血管(CNV)和动脉瘤/息肉。分析有助于诊断 PAT1/PCV 的成像特征。

结果:共纳入 44 例患者的 49 只眼,临床诊断为 PNV,其中 42 只眼(85.7%)为 PNV,7 只眼(14.3%)为误诊的 PAT1/PCV。SFCT 无差异(PNV:377±92µm;PAT1/PCV:400±83µm;p=0.39)。虽然总色素上皮脱离(PED)直径无差异(p=0.46),但 PAT1/PCV 组的最大 PED 高度显著更高(199±31µm;82±46µm;p<0.00001)。在受试者工作特征(ROC)分析中,定义“高峰 PED”的最佳截断值为 158µm,曲线下面积为 0.969,灵敏度为 1.0(95%CI:0.59-1.0),特异性为 0.95(95%CI:0.84-0.99)。视网膜下高反射物质(SHRM;p=0.04)、视网膜下环状结构(SRRLS;p<0.00001)和视网膜下液(p=0.04)在 PAT1/PCV 眼中更为常见。

结论:被诊断为 PNV 的眼可能有相当比例实际上患有 PAT1/PCV。检测最大PED 高度(“高峰 PED”)超过约 150µm、SHRM、SRRLS 和视网膜下液可能极大地有助于更准确地诊断。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca9b/10630494/ef2ec1360dd0/41433_2023_2529_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca9b/10630494/5bca831dfb95/41433_2023_2529_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca9b/10630494/cf5761fa09b5/41433_2023_2529_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca9b/10630494/ef2ec1360dd0/41433_2023_2529_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca9b/10630494/5bca831dfb95/41433_2023_2529_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca9b/10630494/cf5761fa09b5/41433_2023_2529_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca9b/10630494/ef2ec1360dd0/41433_2023_2529_Fig3_HTML.jpg

相似文献

[1]
Optical coherence tomography-based misdiagnosis and morphological distinction in pachychoroid neovasculopathy vs. polypoidal choroidal vasculopathy.

Eye (Lond). 2023-11

[2]
Progression of Pachychoroid Neovasculopathy into Aneurysmal Type 1 Choroidal Neovascularization or Polypoidal Choroidal Vasculopathy.

Ophthalmol Retina. 2022-9

[3]
Vortex Vein Anastomosis at the Watershed in Pachychoroid Spectrum Diseases.

Ophthalmol Retina. 2020-9

[4]
A comparative study of type 1 neovascularization: Neovascular age-related macular degeneration versus pachychoroid neovasculopathy.

Eur J Ophthalmol. 2022-7

[5]
IMPROVED DETECTION AND DIAGNOSIS OF POLYPOIDAL CHOROIDAL VASCULOPATHY USING A COMBINATION OF OPTICAL COHERENCE TOMOGRAPHY AND OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY.

Retina. 2019-9

[6]
Small dome-shaped pigment epithelium detachment in polypoidal choroidal vasculopathy: an under-recognized sign of polypoidal lesions on optical coherence tomography?

Eye (Lond). 2022-4

[7]
Imaging characterization of the fellow eye in patients with unilateral polypoidal choroidal vasculopathy.

Int Ophthalmol. 2024-3-1

[8]
Quantitative measures of vortex veins in the posterior pole in eyes with pachychoroid spectrum diseases.

Sci Rep. 2020-11-11

[9]
Differentiating Exudative Macular Degeneration and Polypoidal Choroidal Vasculopathy Using OCT B-Scan.

Ophthalmol Retina. 2021-10

[10]
Sensitivity and Specificity of Potential Diagnostic Features Detected Using Fundus Photography, Optical Coherence Tomography, and Fluorescein Angiography for Polypoidal Choroidal Vasculopathy.

JAMA Ophthalmol. 2019-6-1

引用本文的文献

[1]
Imaging in Pachychoroid Disease.

Turk J Ophthalmol. 2025-2-27

[2]
Intraocular lens power calculation for silicone oil-dependent eyes.

Front Med (Lausanne). 2023-10-23

[3]
Advances in multi-modal non-invasive imaging techniques in the diagnosis and treatment of polypoidal choroidal vasculopathy.

Front Med (Lausanne). 2023-7-27

本文引用的文献

[1]
Progression of Pachychoroid Neovasculopathy into Aneurysmal Type 1 Choroidal Neovascularization or Polypoidal Choroidal Vasculopathy.

Ophthalmol Retina. 2022-9

[2]
One-year efficacy of "rescue photodynamic therapy" for patients with typical age-related macular degeneration, polypoidal choroidal vasculopathy, and pachychoroid neovasculopathy refractory to anti-vascular endothelial growth factor therapy.

Graefes Arch Clin Exp Ophthalmol. 2022-6

[3]
Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy.

Sci Rep. 2021-6-8

[4]
Two-Thirds Dose Photodynamic Therapy for Pachychoroid Neovasculopathy.

J Clin Med. 2021-5-17

[5]
Photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy.

PLoS One. 2021

[6]
One-year comparison of anti-vascular endothelial growth factor and half-dose photodynamic therapies for pachychoroid neovasculopathy.

Eye (Lond). 2021-12

[7]
The Ambiguity of Pachychoroid.

Retina. 2021-2-1

[8]
Characteristics of pachychoroid neovasculopathy.

Sci Rep. 2020-10-1

[9]
The spectrum of polypoidal choroidal vasculopathy in Caucasians: clinical characteristics and proposal of a classification.

Graefes Arch Clin Exp Ophthalmol. 2021-2

[10]
Polypoidal Choroidal Vasculopathy: Consensus Nomenclature and Non-Indocyanine Green Angiograph Diagnostic Criteria from the Asia-Pacific Ocular Imaging Society PCV Workgroup.

Ophthalmology. 2021-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索